Teva Pharmaceutical Industries Limited (TEVA) — Financial statements
Income statement, balance sheet, and cash flow for Teva Pharmaceutical Industries Limited — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 17,257↑4.3% | 16,544↑4.4% | 15,845↑6.2% | 14,925↓6.0% | 15,878 | |
| Cost of Revenue | 8,320↓1.9% | 8,481↑3.4% | 8,200↑3.1% | 7,952↓4.0% | 8,284 | |
| Gross Profit | 8,938↑10.9% | 8,063↑5.5% | 7,645↑9.6% | 6,973↓8.2% | 7,594 | |
| Operating Expenses | ||||||
| R&D Expenses | 1,013↓4.0% | 1,055↑10.7% | 953↑13.7% | 838↓23.4% | 1,094 | |
| General & Administrative Expenses | 1,287↑10.9% | 1,161↓0.1% | 1,162↓1.5% | 1,180↑7.4% | 1,099 | |
| Selling & Marketing Expenses | 2,686↑5.7% | 2,541↑8.8% | 2,336↑3.1% | 2,265↓6.8% | 2,429 | |
| SG&A Expenses | 3,973↑7.3% | 3,702↑5.8% | 3,498↑1.5% | 3,445↓2.4% | 3,528 | |
| Other Expenses | 1,794↓50.3% | 3,609↑30.7% | 2,761↓43.5% | 4,887↑289.1% | 1,256 | |
| Operating Expenses | 6,780↓19.0% | 8,366↑16.0% | 7,212↓21.4% | 9,170↑56.0% | 5,878 | |
| Total Costs & Expenses | 15,100↓10.4% | 16,847↑9.3% | 15,412↓10.0% | 17,122↑20.9% | 14,162 | |
| Operating Results | ||||||
| Operating Income | 2,157↑811.9% | -303↓170.0% | 433↑119.7% | -2,197↓228.0% | 1,716 | |
| Depreciation & Amortization | 1,002↓5.4% | 1,059↓8.2% | 1,153↓11.9% | 1,308↓1.7% | 1,330 | |
| EBITDA | 3,141↓29.1% | 4,431↑184.4% | 1,558↑268.4% | -925↓121.0% | 4,409 | |
| EBIT | 2,139↓36.6% | 3,372↑732.6% | 405↑118.1% | -2,233↓172.5% | 3,079 | |
| Interest & Other Income | ||||||
| Net Interest Income | -916↑2.7% | -941↑2.1% | -961↓3.3% | -930↓4.4% | -891 | |
| Interest Income | 0.00 | 0.00↓100.0% | 68 | 0.00 | 0.00 | |
| Interest Expense | 916↓2.7% | 941↓8.6% | 1,029↑10.6% | 930↑4.4% | 891 | |
| Non-Operating Income | 18↑100.5% | -3,675↓13225.0% | 28↓22.2% | 36↑102.6% | -1,363 | |
| Other Income / Expenses | -919↑6.2% | -980↑7.1% | -1,055↓11.6% | -945↑9.9% | -1,049 | |
| Income Before Tax | 1,238↑196.5% | -1,283↓106.3% | -622↑80.2% | -3,142↓571.1% | 667 | |
| Income Tax Expense | -180↓126.6% | 676↑9757.1% | -7↑98.9% | -643↓404.7% | 211 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 1,418↑172.4% | -1,959↓218.5% | -615↑75.4% | -2,499↓648.0% | 456 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 1,410↑186.0% | -1,639↓193.2% | -559↑77.1% | -2,446↓686.6% | 417 | |
| Bottom-Line Net Income | 1,410↑186.0% | -1,639↓193.2% | -559↑77.1% | -2,446↓686.6% | 417 | |
| EPS (Basic) | 1.23↑184.8% | -1.45↓190.0% | -0.50↑77.3% | -2.20↓678.9% | 0.38 | |
| EPS (Diluted) | 1.20↑182.8% | -1.45↓190.0% | -0.50↑77.3% | -2.20↓678.9% | 0.38 | |
| Weighted Average Shares | 1,149↑1.6% | 1,131↑1.1% | 1,119↑0.8% | 1,110↑0.7% | 1,102 | |
| Weighted Average Diluted Shares | 1,173↑3.7% | 1,131↑1.1% | 1,119↑0.8% | 1,110↑0.3% | 1,107 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.